Cytokinetics. has been granted a patent for compounds of Formula (I) and their pharmaceutically acceptable salts. The patent includes methods for preparing these compounds and compositions containing them, indicating potential applications in pharmaceuticals. GlobalData’s report on Cytokinetics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Cytokinetics, NSAID cancer drugs was a key innovation area identified from patents. Cytokinetics's grant share as of July 2024 was 41%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12065436B2 outlines a method for preparing a compound designated as formula (A). The process begins with the conversion of a precursor compound, referred to as formula (15-3), into the target compound (A) through a reaction with 1-methyl-1H-pyrazole-4-carboxylic acid or its salt. This reaction can be facilitated by the presence of specific reagents, including 1-hydroxy-7-azabenzotriazole (HOAt) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDCI), or alternatively, diisopropylethylamine. The method also includes steps to obtain the compound of formula (15-3) from another precursor, formula (15-2), which is converted using trifluoroacetic acid.
Further elaboration in the claims details the multi-step synthesis process, where the compound of formula (15-2) is derived from formula (5-4) through a reaction with propanoyl propanoate, typically conducted in dioxane at approximately 105°C. The synthesis continues back through several intermediates, including the conversion of formula (5-4) from formula (5-3) using hydroxylamine, and the preparation of formula (5-3) from formula (5-2) via a reaction with potassium ferricyanide (K4Fe(CN)6·3H2O) in the presence of potassium acetate and specific phosphine ligands. The initial compound, (1R)-5-bromo-2,3-dihydro-1H-inden-1-amine, is also specified as a starting material, which can be converted to formula (5-2) using di-tert-butyl dicarbonate. The detailed claims provide a comprehensive roadmap for synthesizing the target compound through a series of well-defined chemical transformations.
To know more about GlobalData’s detailed insights on Cytokinetics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
